Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, 20892, USA.
Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, 20892, USA.
Cardiovasc Intervent Radiol. 2021 Sep;44(9):1439-1447. doi: 10.1007/s00270-021-02853-x. Epub 2021 May 21.
To evaluate an integrated liver biopsy platform that combined CT image fusion, electromagnetic (EM) tracking, and optical molecular imaging (OMI) of indocyanine green (ICG) to target hepatocellular carcinoma (HCC) lesions and a point-of-care (POC) OMI to assess biopsy cores, all based on tumor retention of ICG compared to normal liver, in phantom and animal model.
A custom CT image fusion and EM-tracked guidance platform was modified to integrate the measurement of ICG fluorescence intensity signals in targeted liver tissue with an OMI stylet or a POC OMI system. Accuracy was evaluated in phantom and a woodchuck with HCC, 1 day after administration of ICG. Fresh biopsy cores and paraffin-embedded formalin-fixed liver tissue blocks were evaluated with the OMI stylet or POC system to identify ICG fluorescence signal and ICG peak intensity.
The mean distance between the initial guided needle delivery location and the peak ICG signal was 5.0 ± 4.7 mm in the phantom. There was complete agreement between the reviewers of the POC-acquired ICG images, cytology, and histopathology in differentiating HCC-positive from HCC-negative biopsy cores. The peak ICG fluorescence intensity signal in the ex vivo liver blocks was 39 ± 12 and 281 ± 150 for HCC negative and HCC positive, respectively.
Biopsy guidance with fused CT imaging, EM tracking, and ICG tracking with an OMI stylet to detect HCC is feasible. Immediate assessment of ICG uptake in biopsy cores with the POC OMI system is feasible and correlates with the presence of HCC in the tissue.
评估一种集成的肝活检平台,该平台结合 CT 图像融合、电磁(EM)跟踪和吲哚菁绿(ICG)的光学分子成像(OMI)来靶向肝细胞癌(HCC)病变,并结合基于肿瘤对 ICG 的保留程度的即时护理(POC)OMI 来评估活检芯,所有这些都与正常肝脏相比,在体模和动物模型中。
定制的 CT 图像融合和 EM 跟踪引导平台经过修改,以整合靶向肝组织中 ICG 荧光强度信号的测量,同时集成 OMI 活检针或 POC OMI 系统。在体模和接受 ICG 治疗后 1 天的土拨鼠 HCC 模型中评估了准确性。使用 OMI 活检针或 POC 系统评估新鲜活检芯和石蜡包埋福尔马林固定的肝组织块,以识别 ICG 荧光信号和 ICG 峰值强度。
在体模中,初始引导针输送位置和 ICG 信号峰值之间的平均距离为 5.0±4.7mm。POC 获得的 ICG 图像、细胞学和组织病理学在区分 HCC 阳性和 HCC 阴性活检芯方面,两位评审者的意见完全一致。在离体肝块中,ICG 荧光强度信号的峰值分别为 HCC 阴性和 HCC 阳性的 39±12 和 281±150。
使用融合 CT 成像、EM 跟踪和 OMI 活检针的 ICG 跟踪引导 HCC 活检是可行的。使用 POC OMI 系统即时评估活检芯中的 ICG 摄取是可行的,并且与组织中 HCC 的存在相关。